Endpoints News

An unusual gene therapy approach for brain cancer		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T Wed Th F

18 February, 2026

CGT has fresh momentum from new FDA frameworks and pharma deals, but do the latest advances in science, manufacturing, and regulation actually solve the core challenges? We’re asking the hard questions — join us.

presented by

Lessons in Category Creation: In Conversation with Bobby Azamian, CEO Tarsus Pharmaceuticals

news

FDA reverses course, will review Moderna’s flu vaccine

Chinese biotech claims promising brain cancer results using debated approach

Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront

Paragon's latest biotech will try to slow Alzheimer's like Roche

Leo Pharma says it's turned a profit for the first time in seven years

Client Engagement Mgr - Life Sciences Strategy & Intelligence

Sedulo Group

United States

Vice President, Drug Metabolism & Pharmacokinetics (DMPK)

C4 Therapeutics

Watertown, MA, USA

Recruit talent with Endpoints Careers

Contact Meg Estacio: mestacio@endpointsnews.com

Innovation in biopharmaceuticals: A conversation with Fujifilm leaders

in case you missed it

Compass Pathways soars as psilocybin depression treatment hits second Phase 3 trial goals

Moderna faces setback in Arbutus' long-running mRNA patent fight

Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink

FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher

News Briefing

Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters

Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapy

Bayer retreats as investors sour on deal to settle Roundup litigation

Danaher strikes $10B deal for medical device maker Masimo

Lilly's dealmaking spree continues, and this time it's with CSL for its IL-6 drug clazakizumab. Lilly's plans for the asset are unclear, but the move could pit it against companies like Novo Nordisk and Novartis (after its Tourmaline Bio acquisition). Check out the licensing details here.